Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
Status:
Temporarily Closed
Phase 2 Study of Nivolumab and BMS-986016 (Relatlimab) in Patients with LAG-3+ Tumors with Mismatch Repair Deficiency (MMR-d) after Progression on Anti-PD-1/PD-L1 Therapy
(See required screening study ECOG-ACRIN EAY131)
Accrual to EAY131-Z1M is suspended, effective January 17,2023.
NCT#02465060